Adagio Therapeutics, Inc. (ADGI) News
Filter ADGI News Items
ADGI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADGI News Highlights
- ADGI's 30 day story count now stands at 3.
- Over the past 6 days, the trend for ADGI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BA are the most mentioned tickers in articles about ADGI.
Latest ADGI News From Around the Web
Below are the latest news stories about ADAGIO THERAPEUTICS INC that investors may wish to consider to help them evaluate ADGI as an investment opportunity.
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsIntegrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1Antibodies target highly conserved epitopes under low immune pressure NVD200, a novel combination of two monoclonal antibodies, expected to advance into clinical trials in Q1 2023 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, |
Adagio Therapeutics Announces Corporate Name Change to InvivydNew name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission is to provide antibody solutions that provide superior protection against viral diseases, starting with COVID-19Company’s shares to trade under new ticker symbol “IVVD” starting on September 13 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, (Nasdaq: ADGI), a clinical-stage |
Adagio Therapeutics to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference: Management will participate in a fireside chat on Monday, September 12, 2022, at 2:50 |
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Quarter of 2023 WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infecti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Billionaire Dan Loeb is Adding These 9 Stocks in his PortfolioIn this article, we will discuss the 9 stocks billionaire Dan Loeb is adding to his portfolio. If you want to skip reading about Dan Loeb’s investment philosophy and his hedge fund’s performance, you can go directly to Billionaire Dan Loeb is Adding These 5 Stocks in his Portfolio. Daniel Seth Loeb is an American […] |
The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drugThe FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm. |
Is Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignAUSTIN, Texas, July 05, 2022--Mithril Capital Management LLC ("Mithril"), a founding investor in and the leader of a consortium of investors that represented approximately 49% of the outstanding shares of Adagio Therapeutics, Inc. (Nasdaq: ADGI) ("Adagio"), today issued a letter to fellow Adagio shareholders thanking them for helping to ensure Adagio is best-positioned to advance its public health mission and build on the outstanding technology that underpins its platform. |
Adagio Announces David Hering Named Permanent Chief Executive Officer and DirectorWALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that industry and infectious disease veteran David Hering, who has been serving as the company’s interim chief executive officer and chief operating officer, has been named permanent CEO and a director on the company’s Board of Director |